Desalting and Buffer Exchange Market Overview:
The global market for desalting and buffer exchange is expected to grow at a CAGR of 10.5 percent over the assessment period, according to MRFR research findings. According to the research, the market was worth USD 615.20 million in 2017. Desalting is a method for separating soluble low molecular weight compounds from nucleic acid and protein samples. Buffer exchange, on the other hand, is the process of replacing one set of buffer salts with another.
Furthermore, buffer exchange is an important step in the processing of biological samples, since it prepares the material for downstream uses. In recent years, the worldwide desalting and buffer exchange sector have seen tremendous expansion. Furthermore, factors such as increased research and development investment by major biopharmaceutical firms, as well as a growing focus on proteomic and genomic research, are expected to support market growth throughout the forecast period.
The Desalting and Buffer Exchange Market has been segmented into technique, product, and application. On the basis of technique, the market has been segmented into filtration, chromatography, and precipitation. The filtration segment has been further segmented into ultrafiltration and dialysis. The chromatography segment has been segmented into size-exclusion chromatography and others.
The market, by product, has been segmented into kits, cassettes, filter plates, spin columns, membrane filters, and others.
The market, by application, has been segmented into bioprocess applications and diagnostic applications. The bioprocess segment is expected to account for the largest market share in 2017. The market growth of the segment is attributed to the increasing demand for biopharmaceutical products.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The desalting and buffer exchange market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European desalting and buffer exchange market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The desalting and buffer exchange market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The desalting and buffer exchange market in the Middle East & Africa has been segmented into the Middle East and Africa.
Merck KGaA, GE Healthcare, Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Avantor, Repligen Corporation, Bio-works Technologies Ab, Phynexus, Inc., and Norgen Biotek Corp. are some of the key players in the desalting and buffer exchange market.
Regional Market Summary
Global Desalting and Buffer Exchange Market Share (%), by Region, 2017
Source: Office of National Statistics, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the desalting and buffer exchange market owing to the rising demand for biopharmaceuticals, rising R&D expenditure by biopharmaceutical companies, and increasing research activities in the field of genomics and proteomics.
Europe is expected to hold the second largest position in the desalting and buffer exchange market. The market growth in this region is attributed to the increasing number of research and development activities in the region.
The desalting and buffer exchange market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the continuously growing biotechnology sector and increasing regional expansion by prominent market players.
The Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Agilent Technologies, Inc. (Agilent or 'the firm') provides equipment, software, services, and consumables that enable clients in the clinical and life sciences research fields to identify, analyze, and measure the biological and physical characteristics of substances and products. Pharmaceutical and biopharmaceutical companies, academia and government, chemical and energy companies, environmental and forensics companies, diagnostics and clinical companies, and food companies all use the company's services. California is the company's headquarters.
PhyNexus, Inc., a privately owned California firm, said today that it has agreed to be purchased by Biotage AB (Nasdaq Stockholm: BIOT.ST), enhancing its position in the global sales and marketing of automated lab-scale biomolecule purification technology. PhyNexus and Biotage will be able to provide its worldwide clients a platform based on Dual Flow Chromatography and unique tip technology for high throughput purification of biomolecules such as proteins, plasmids, and antibodies at the lab scale.
Desalting and Buffer Exchange Market, by Technique
Desalting and Buffer Exchange Market, by Product
Desalting and Buffer Exchange Market, by Application
Desalting and Buffer Exchange Market, by Region
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Technique, Product, and Application|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Merck KGaA, GE Healthcare, Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Avantor, Repligen Corporation, Bio-works Technologies Ab, Phynexus, Inc., and Norgen Biotek Corp.|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
The desalting and buffer exchange market is projected to grow at a 10.5% CAGR between 2018-2023.
The Americas is projected to command the largest share in the desalting and buffer exchange market.
The bioprocess segment will have the largest share in the desalting and buffer exchange market.
Increasing R&D expenditure and demand for monoclonal antibodies are boosting market growth.
Lack of skilled professionals may limit market growth.